Amphotericin B

Amphotericin B is a polyene macrolide antifungal antibiotic originally isolated from Streptomyces nodosus, representing one of the oldest and most potent systemic antifungal agents available for treating life-threatening mycoses. In farm animal medicine, amphotericin B serves as a critical treatment option for serious systemic fungal infections that fail to respond to other therapies or when organisms known to be susceptible are identified. Despite its age, this compound remains relevant due to its broad spectrum of activity against many pathogenic fungi and yeasts.

The mechanism of action of amphotericin B involves binding to ergosterol, the primary sterol component of fungal cell membranes. This binding creates pores in the membrane, leading to leakage of intracellular contents and ultimately fungal cell death. The selectivity for fungal cells derives from the higher affinity of amphotericin B for ergosterol compared to cholesterol, the predominant sterol in mammalian cell membranes. However, this selectivity is incomplete, which accounts for the drug's significant toxicity profile.

Conventional amphotericin B deoxycholate formulation has been available for decades, while newer lipid-based formulations including liposomal amphotericin B, amphotericin B lipid complex, and amphotericin B colloidal dispersion offer improved safety profiles with reduced nephrotoxicity. These lipid formulations allow higher doses and longer treatment courses while minimizing the renal damage that limits conventional amphotericin B use. However, the significantly higher cost of lipid formulations restricts their use in food animal medicine.

In farm animal practice, amphotericin B use is primarily extra-label, as no formulations are specifically approved for food-producing species in most countries. This necessitates extended withdrawal periods, careful documentation, and veterinary oversight to ensure food safety. The drug is reserved for serious, life-threatening fungal infections where the value of the individual animal justifies the expense and where other treatment options have failed or are inappropriate.

Systemic aspergillosis represents one of the primary indications for amphotericin B use in farm animals. Aspergillus species can cause respiratory disease, abortion, and disseminated infections in cattle, horses, and poultry. In cattle, aspergillosis may present as bronchopneumonia, mycotic placentitis leading to abortion, or ruminal mycosis. Treatment with amphotericin B is most successful when initiated early in the disease course before extensive tissue damage occurs.

Cryptococcal infections in farm animals, though relatively uncommon, may require amphotericin B therapy. Cryptococcus neoformans and related species can cause mastitis in cattle, respiratory disease, and central nervous system infections. The severity of cryptococcosis and the poor penetration of many antifungals into affected tissues make amphotericin B a valuable treatment option despite its toxicity concerns.

Candidiasis in various forms may affect farm animals, particularly in immunocompromised individuals or following prolonged antibiotic therapy that disrupts normal flora. Oral and gastrointestinal candidiasis in calves, ruminal candidiasis following antibiotic treatment, and reproductive tract infections may respond to amphotericin B therapy. Localized candidal infections of the udder causing mastitis have been treated with intrauterine or intramammary amphotericin B preparations.

Histoplasmosis and blastomycosis, endemic mycoses found in certain geographic regions, occasionally affect farm animals and may require amphotericin B treatment. These infections typically present as chronic respiratory disease or disseminated illness and can be difficult to diagnose definitively. Amphotericin B provides reliable activity against these dimorphic fungi when systemic therapy is indicated.

Mycotic abortion caused by various fungal organisms remains a concern in cattle and other livestock. While treatment of infected pregnant animals is rarely successful in saving the pregnancy, therapy may prevent systemic spread and save the dam. Zygomycete infections, including those caused by Mucor and Rhizopus species, show variable susceptibility to amphotericin B but may respond when treatment is initiated promptly.

Intravenous administration of conventional amphotericin B deoxycholate in cattle typically begins at low doses of 0.25 to 0.5 mg/kg body weight, administered as a slow infusion over 2 to 6 hours. The drug must be reconstituted with sterile water for injection and diluted in 5% dextrose solution; saline solutions cause precipitation and must not be used. Test doses are often recommended before full therapy to assess for immediate hypersensitivity reactions.

Dose escalation protocols involve gradually increasing the amphotericin B dose over several days to the target maintenance dose of 0.5 to 1.0 mg/kg, administered every 24 to 48 hours. Total cumulative doses in cattle may reach 10 to 20 mg/kg over the complete treatment course, though this varies with the specific infection and clinical response. Monitoring renal function through serum creatinine and blood urea nitrogen levels helps guide dose adjustments.

For intrauterine treatment of mycotic endometritis or post-abortion complications, amphotericin B may be infused directly into the uterus at doses of 100 to 200 mg diluted in sterile saline. This local administration achieves high concentrations at the site of infection while minimizing systemic exposure and toxicity. Multiple treatments at 24 to 48-hour intervals may be necessary for adequate response.

Topical formulations of amphotericin B find use in treating superficial fungal infections and keratomycosis. Ophthalmic preparations containing 0.1% to 0.5% amphotericin B can be compounded for treating fungal keratitis in cattle and horses. Application frequency varies from every 2 hours in acute cases to 3 to 4 times daily during maintenance therapy.

Lipid-based amphotericin B formulations allow higher doses of 3 to 5 mg/kg daily with reduced nephrotoxicity compared to conventional deoxycholate preparations. While these formulations are considerably more expensive, they may be justified for valuable breeding animals or when conventional amphotericin B toxicity limits therapy. Liposomal formulations also penetrate better into certain tissues including the central nervous system.

Withdrawal times for amphotericin B in food-producing animals are not established by regulatory agencies due to lack of tissue residue data. Extended withdrawal periods of 60 to 90 days or longer are typically recommended when extra-label use occurs, and producers should consult the Food Animal Residue Avoidance Databank for current guidance. Documentation of use and consultation with regulatory veterinarians is essential before treated animals enter the food chain.

Nephrotoxicity represents the most significant adverse effect of amphotericin B therapy in all species. The drug causes dose-dependent reduction in renal blood flow and direct tubular damage, leading to decreased glomerular filtration rate, azotemia, and electrolyte wasting. Signs of renal impairment include decreased urine output, increased serum creatinine, elevated blood urea nitrogen, and potassium and magnesium depletion. Regular monitoring of renal function parameters is essential during therapy.

Infusion-related reactions occur commonly with conventional amphotericin B administration and may include fever, chills, rigors, nausea, vomiting, and hypotension. These reactions typically occur during or shortly after infusion and can be severe enough to require discontinuation of therapy. Pretreatment with antipyretics, antihistamines, or corticosteroids may reduce the severity of these reactions. Slowing the infusion rate also helps minimize acute adverse effects.

Electrolyte abnormalities frequently accompany amphotericin B therapy due to renal tubular damage and increased urinary losses. Hypokalemia and hypomagnesemia are particularly common and can lead to muscle weakness, cardiac arrhythmias, and neurological disturbances. Supplementation with potassium and magnesium may be necessary during extended treatment courses, with monitoring of serum electrolyte levels guiding replacement therapy.

Anemia develops with prolonged amphotericin B administration, likely due to suppression of erythropoietin production and direct bone marrow effects. This normochromic, normocytic anemia is generally reversible upon discontinuation of therapy but may require blood transfusion in severe cases. Monitoring packed cell volume during extended treatment helps identify this complication before it becomes clinically significant.

Local reactions at injection sites include thrombophlebitis when peripheral veins are used for infusion. Central venous access is preferred for extended amphotericin B therapy to preserve peripheral vein integrity. Extravasation of amphotericin B causes tissue necrosis and must be avoided through careful catheter placement and monitoring during infusion.

Pre-existing renal insufficiency represents a relative contraindication to amphotericin B therapy, as the drug will likely cause further deterioration of kidney function. Animals with elevated creatinine or decreased urine output should be evaluated carefully before initiating therapy, with risk-benefit assessment considering the severity of the fungal infection versus the potential for permanent renal damage. Lipid formulations may be preferred when available for animals with compromised renal function.

Known hypersensitivity to amphotericin B or any formulation components contraindicates further use. Severe infusion reactions during initial dosing may represent true anaphylaxis requiring permanent discontinuation of the drug. Test doses help identify animals likely to experience severe reactions before full therapeutic doses are administered.

Concurrent administration of other nephrotoxic drugs should be avoided during amphotericin B therapy when possible. Aminoglycoside antibiotics, non-steroidal anti-inflammatory drugs, and certain other medications add to the renal insult and increase the risk of acute kidney injury. When concurrent nephrotoxic therapy is unavoidable, enhanced monitoring and dose adjustments may help minimize additive toxicity.

Dehydrated animals should be rehydrated before initiating amphotericin B therapy. Volume depletion concentrates the drug in renal tissue and exacerbates nephrotoxicity. Adequate fluid intake and maintenance of euvolemia throughout treatment helps protect renal function and should be ensured before each infusion.

Aminoglycoside antibiotics including gentamicin, amikacin, and streptomycin produce additive nephrotoxicity when combined with amphotericin B. This combination significantly increases the risk of acute tubular necrosis and permanent renal damage. When both drug classes are required for polymicrobial infections, staggering doses, reducing individual drug doses, and intensive monitoring of renal function are essential precautions.

Potassium-depleting drugs including loop diuretics and corticosteroids may exacerbate the hypokalemia caused by amphotericin B. Concurrent use requires careful monitoring of serum potassium levels and supplementation as needed to prevent cardiac arrhythmias and muscle weakness. Potassium-sparing diuretics may partially offset this effect but should be used cautiously given amphotericin B's effects on renal function.

Cyclosporine and other immunosuppressive agents interact with amphotericin B through multiple mechanisms. The combination increases nephrotoxicity risk while cyclosporine levels may be altered by amphotericin B effects on drug metabolism. Animals receiving concurrent immunosuppressive therapy require particularly close monitoring of both drug levels and renal function.

Flucytosine, another antifungal agent, is often combined with amphotericin B for synergistic activity against certain fungi including Cryptococcus. While this combination provides therapeutic benefit, flucytosine toxicity may increase due to amphotericin B-induced renal impairment reducing flucytosine clearance. Dose adjustment of flucytosine based on renal function and drug level monitoring optimizes this combination therapy.

Human safety during amphotericin B handling requires standard precautions for cytotoxic drugs. Reconstitution and dilution should occur in appropriate biosafety cabinets when available, with handlers wearing gloves and avoiding aerosol generation. Pregnant women should not handle amphotericin B preparations due to unknown reproductive effects. Proper disposal of unused drug and administration equipment follows hazardous pharmaceutical waste protocols.

Food safety considerations are paramount given the extra-label nature of amphotericin B use in food-producing animals. Extended withdrawal times of 60 to 90 days or longer are typically required, though specific guidance should be obtained from the Food Animal Residue Avoidance Databank for current recommendations. Complete treatment records including drug lot numbers, doses, dates, and intended withdrawal periods must be maintained for regulatory compliance.

Renal function monitoring throughout amphotericin B therapy helps prevent permanent kidney damage. Baseline creatinine and blood urea nitrogen values should be obtained before initiating therapy, with follow-up testing every 24 to 48 hours during active treatment. Rising creatinine levels may necessitate dose reduction, extended dosing intervals, or temporary cessation of therapy to allow renal recovery.

Electrolyte monitoring and supplementation address the common complications of hypokalemia and hypomagnesemia. Serum potassium should be maintained above 3.5 mEq/L, with oral or intravenous supplementation as needed. Magnesium deficiency may require parenteral replacement if oral supplementation proves inadequate. These electrolyte disturbances can be life-threatening if unrecognized and untreated.

Hydration status significantly impacts amphotericin B nephrotoxicity. Saline loading before each infusion, typically with 500 to 1000 mL of 0.9% saline administered over 1 to 2 hours in cattle-sized animals, helps protect renal function by maintaining renal blood flow. This prehydration protocol is considered standard of care for conventional amphotericin B administration and reduces the incidence of renal complications.

Amphotericin B deoxycholate powder for reconstitution should be stored under refrigeration at 2°C to 8°C (36°F to 46°F) and protected from light. The lyophilized powder is stable for several years when properly stored in original packaging. Once reconstituted with sterile water, the solution may be stored under refrigeration for up to 24 hours but should be protected from light to prevent degradation.

Reconstituted amphotericin B diluted in 5% dextrose for infusion should be used within 24 hours and protected from light during administration. Light-protective covers for infusion bags and tubing reduce drug degradation during prolonged infusions. Solutions that become cloudy or contain visible precipitates should be discarded, as this indicates chemical degradation or incompatibility.

Lipid-based amphotericin B formulations have specific storage requirements that vary by product. Liposomal preparations may require refrigeration, while amphotericin B lipid complex products might be stable at room temperature. Consult individual product labeling for specific storage conditions and expiration dating. Once diluted for infusion, these products also have limited stability and should be used promptly. Disposal of expired or unused amphotericin B products follows hazardous pharmaceutical waste guidelines. The drug should not be disposed of through regular trash or wastewater systems. Incineration at licensed facilities or return to pharmaceutical waste disposal programs ensures environmental safety and regulatory compliance.

Cattle breeds show variable tolerance to the nephrotoxic effects of amphotericin B, with some evidence suggesting that Bos indicus breeds may be more sensitive to renal insults than Bos taurus breeds. Individual variation in renal reserve affects toxicity risk, with older animals and those with any pre-existing renal compromise at increased risk. Baseline renal function assessment before therapy helps identify high-risk individuals.

Dairy cattle treated with amphotericin B present particular challenges regarding milk withdrawal. No established milk withdrawal time exists, and treated animals should not have milk sold for human consumption for extended periods. The economic impact of discarded milk must be weighed against treatment benefits when deciding whether to treat valuable dairy individuals with systemic fungal infections.

Beef cattle destined for slaughter require extended meat withdrawal periods following amphotericin B treatment. The lack of established tissue residue data means conservative withdrawal recommendations of 60 to 90 days or longer apply. This may render treatment economically impractical for commercial beef animals unless individual value justifies the extended holding period.

Breeding stock, particularly valuable bulls and heifers, represent the population most likely to receive amphotericin B therapy in food animal practice. The higher individual value justifies the treatment expense and extended withdrawal periods. Monitoring for any reproductive effects is warranted, though limited data exist on amphotericin B effects on fertility in farm animal species.

Nystatin, another polyene antifungal, shares amphotericin B's mechanism of action but is limited to topical and gastrointestinal use due to poor systemic absorption. Nystatin finds application in treating oral and intestinal candidiasis in farm animals without the nephrotoxicity concerns of systemic amphotericin B. The drug is available in oral suspensions and topical formulations for local fungal infections.

Azole antifungals including fluconazole, itraconazole, and ketoconazole offer oral alternatives to parenteral amphotericin B for some fungal infections. These drugs inhibit ergosterol synthesis rather than binding directly to the cell membrane sterol. Their reduced toxicity and oral availability make them attractive first-line options for many mycoses, reserving amphotericin B for azole-resistant infections or severe systemic disease.

Echinocandin antifungals including caspofungin and micafungin represent a newer class with activity against Aspergillus and Candida species. These drugs inhibit fungal cell wall synthesis and have reduced nephrotoxicity compared to amphotericin B. Limited use in farm animals relates to cost and lack of approved formulations, but they may serve as alternatives in specific situations where amphotericin B toxicity is prohibitive.